This is a preview of subscription content, log in via an institution to check access.
Notes
Under AMNOG, the annual treatment costs must not exceed those of the appropriate comparator.
Reference
Cell Therapeutics Inc. German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI (pixantrone). Media Release : 20 May 2013. Available from: URL: http://www.celltherapeutics.com
Rights and permissions
About this article
Cite this article
G-BA says additional benefit for pixantrone not determined. PharmacoEcon Outcomes News 679, 10 (2013). https://doi.org/10.1007/s40274-013-0448-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0448-9